SG11202002460QA - Selective p2x3 modulators - Google Patents

Selective p2x3 modulators

Info

Publication number
SG11202002460QA
SG11202002460QA SG11202002460QA SG11202002460QA SG11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA SG 11202002460Q A SG11202002460Q A SG 11202002460QA
Authority
SG
Singapore
Prior art keywords
modulators
selective
Prior art date
Application number
SG11202002460QA
Other languages
English (en)
Inventor
Denis Garceau
Antonios Matzouranis
Roberto Bellini
Kemal Payza
Nathalie Chauret
Susan Browne
Original Assignee
Bellus Health Cough Inc
Neomed Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc, Neomed Inst filed Critical Bellus Health Cough Inc
Publication of SG11202002460QA publication Critical patent/SG11202002460QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
SG11202002460QA 2017-09-18 2018-09-14 Selective p2x3 modulators SG11202002460QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560077P 2017-09-18 2017-09-18
US15/936,316 US10111883B1 (en) 2017-09-18 2018-03-26 Selective P2X3 modulators
PCT/IB2018/001513 WO2019064079A2 (fr) 2017-09-18 2018-09-14 Modulateurs sélectifs de p2x3

Publications (1)

Publication Number Publication Date
SG11202002460QA true SG11202002460QA (en) 2020-04-29

Family

ID=63894683

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002460QA SG11202002460QA (en) 2017-09-18 2018-09-14 Selective p2x3 modulators

Country Status (12)

Country Link
US (6) US10111883B1 (fr)
EP (2) EP3684368B8 (fr)
JP (1) JP7242681B2 (fr)
KR (1) KR20200092938A (fr)
CN (1) CN111601601A (fr)
AU (1) AU2018342751B2 (fr)
CA (1) CA3076150C (fr)
ES (1) ES2969868T3 (fr)
IL (2) IL273348B2 (fr)
MX (1) MX2020002968A (fr)
SG (1) SG11202002460QA (fr)
WO (1) WO2019064079A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559104A (zh) * 2018-10-05 2021-10-29 盐野义制药株式会社 慢性咳嗽治疗用药物
JP2022512652A (ja) * 2018-10-10 2022-02-07 べルス・ヘルス・コフ・インコーポレーテッド Ｐ２ｘ３拮抗薬での皮膚掻痒症の治療
MX2021005424A (es) * 2018-11-13 2021-06-15 Bellus Health Cough Inc Formas cristalinas de un compuesto de imidazopiridina sustituida y uso del mismo como modulador del receptor p2x3.
SG11202106706TA (en) * 2018-12-29 2021-07-29 Wuhan Ll Science And Technology Development Co Ltd Heterocyclic compound intermediate, preparation method therefor and application thereof
AU2020228760A1 (en) * 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN115413279A (zh) * 2020-02-14 2022-11-29 贝卢斯医疗咳嗽病公司 P2x3调节剂
BR112022021789A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
CA3184482A1 (fr) * 2020-06-29 2022-01-06 Liang Wang Forme cristalline d'un compose heterocyclique, son procede de preparation et son utilisation
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
CA3187092A1 (fr) * 2020-08-13 2022-02-17 Wenming Li Derives de benzimidazole, leur procede de preparation et leur utilisation medicale
WO2022161462A1 (fr) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 Dérivé de morpholine, composition pharmaceutique et leur utilisation
WO2022258059A1 (fr) * 2021-06-10 2022-12-15 武汉朗来科技发展有限公司 Composition pharmaceutique, préparation, procédé de préparation et utilisation de cette dernière
CN115043836B (zh) * 2021-08-20 2023-07-18 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542582C2 (ru) * 2009-11-18 2015-02-20 Астразенека Аб Производные бензимидазола, полезные при лечении состояний, ассоциированных с активностью р2х3 или р2х2/3
CN105246888B (zh) 2013-01-31 2017-09-05 尼奥迈德研究所 咪唑并吡啶化合物及其用途
MY195728A (en) * 2013-08-23 2023-02-07 Afferent Pharmaceuticals Inc Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough
JP6877441B2 (ja) 2015-09-29 2021-05-26 アファレント ファーマシューティカルズ インコーポレイテッド 咳の処置における使用のためのジアミノピリミジンｐ２ｘ３及びｐ２ｘ２／３受容体修飾因子
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
RU2019112740A (ru) * 2016-09-30 2020-11-02 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи P2x3 и/или p2x2/3 соединения и способы

Also Published As

Publication number Publication date
EP4331669A2 (fr) 2024-03-06
WO2019064079A3 (fr) 2019-05-16
KR20200092938A (ko) 2020-08-04
WO2019064079A2 (fr) 2019-04-04
CA3076150C (fr) 2024-01-02
US20200230148A1 (en) 2020-07-23
CN111601601A (zh) 2020-08-28
IL273348B2 (en) 2023-11-01
US20230248736A1 (en) 2023-08-10
JP7242681B2 (ja) 2023-03-20
ES2969868T3 (es) 2024-05-23
EP3684368B8 (fr) 2024-02-14
EP3684368A4 (fr) 2021-05-26
CA3076150A1 (fr) 2019-04-04
IL303257A (en) 2023-07-01
AU2018342751A1 (en) 2020-04-23
AU2018342751B2 (en) 2023-06-15
US10111883B1 (en) 2018-10-30
EP3684368A2 (fr) 2020-07-29
IL273348A (en) 2020-05-31
EP4331669A3 (fr) 2024-05-01
JP2020534355A (ja) 2020-11-26
IL273348B1 (en) 2023-07-01
MX2020002968A (es) 2020-08-17
US20220160724A1 (en) 2022-05-26
US20210069201A1 (en) 2021-03-11
EP3684368B1 (fr) 2024-01-03
US20210322432A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
IL273348A (en) Selective P2X3 modulators
DK3506981T3 (en) Et transportabelt automatiseret eksternt defibrillator-apparat til engangsbrug
DK3410992T3 (en) Tilbagetrækkeligt udløb til stomipose
ZA201707966B (en) Ccr2 modulators
DK3770053T3 (en) Batterilås til en elcykel
PL3303291T3 (pl) Modulatory ROR-gamma
DK3456957T3 (en) Modvægtssystem til balanceret navvindmølleinstallation
DK3343955T3 (en) Anordning til et høreapparat
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
IL251067A0 (en) p2x7 modulators
DK3457555T3 (en) Drev til et transportsystem
DK3688240T3 (en) Konstruktionssystem til et bygningsmodul
GB201716468D0 (en) Modulators
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORγ)
IL266261A (en) ror-gamma modulators
DK3726976T3 (en) Klimareguleringssystem til insektopdræt
EP3648818C0 (fr) Chambre d'inhalation
DK3481437T3 (en) Precursorer til radiofluorering
GB201703036D0 (en) Methods
SG11201911553VA (en) Adsorption method
DK3430280T3 (en) Magnetisk leje til en turbomaskine
GB2563095B (en) Modulators
DK3615520T3 (en) Methods
DK3558418T3 (en) Et infusionssystem til kortlivede radiofarmaceutika